Psychiatric genomics is made in practice. Developments in psychiatric genomics are the result of an open, contingent process in which different stakeholders -scientists, policymakers, professionals and patients -are involved. This article examines the practices and perspectives of scientists in two long-term, large-scale Dutch psychiatric research consortia that are mapping the origin and development of psychosis, anxiety and depression. The article also explores the perspectives of the funding agency and patients and patient organizations that are in contact with the research consortium on psychoses. What are the issues and concerns of scientists involved in psychiatric genomics, what do they expect genomics will mean for psychiatry, what kind of research are they conducting? What are the issues, concerns and expectations of the main funding agency? How do patients and patient organizations regard developments in psychiatric genomics, and how do they relate to the ongoing research? The conclusion is that different psychiatric futures -not necessarily resulting in geneticized disorders -may emerge from multiple developments in the field. Developments in this case study appear to be contingent on international developments in scientific research; on scientists' different perspectives of what psychiatric disorders are; on national and European traditions in psychiatry, and on the input of patients and patient organizations into research.